The Vanderbilt-Ingram Cancer Center SPORE in lung cancer is committed to reducing the incidence, morbidity and mortality of lung cancer. This team is composed of investigators with expertise in proteomics, cellular and molecular biology, pathology, pulmonary medicine, medical, radiation and surgical oncology, and epidemiology.
The overall goal of the Lung SPORE is to define complex pathways and important intermediates in these pathways to help in the early detection and treatment of lung cancer patients.
The objectives of the Lung SPORE include:
- Applying the translational research strengths at our institution to the clinical problem of lung cancer, which despite medical advances has not seen a dramatic decrease in mortality in the last 15 years
- Assembling a multidisciplinary team of internationally recognized basic and clinical investigators into a cohesive program with a history of progress in the translation of laboratory findings into the clinic and back
- Applying a broad range of state-of-the-art technologies, including leading edge protein mass spectrometry facilities, expertise in signal transduction, eicosanoid and radiation biology, as well as innovative bioinformatics and statistical analysis
- Establishing extensive collaborations with other institutional lung SPOREs, multiple Cooperative Groups, as well as the Breast and GI SPOREs at Vanderbilt
The SPORE in Lung Cancer Team
- William Blot, Ph.D.
- Qiuyin Cai, M.D., Ph.D.
- Pran Datta, Ph.D.
- Adriana Gonzalez, M.D.
- Leora Horn, M.D., M.Sc.
- Stacy Huppert, Ph.D.
- Daniel Liebler, Ph.D.
- Pierre P. Massion, M.D.
- William Pao, M.D., Ph.D.
- Yu Shyr, Ph.D.
- Wei Zheng, M.D., Ph.D., MPH
For more information about the SPORE program, see NCI's SPORE website.